Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Study Investigating the Safety of Stereotactic Body Radiotherapy (SBRT) With Anti-PD1 and Anti-IL-8 for the Treatment of Multiple Metastases in Advanced Solid Tumors and Melanoma

NCT04572451 is registered in ClinicalTrials.gov with Yana Najjar as lead sponsor.

NCT NCT04572451
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04572451 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Study Investigating the Safety of Stereotactic Body Radiotherapy (SBRT) With Anti-PD1 and Anti-IL-8 for the Treatment of Multiple Metastases in Advanced Solid Tumors and Melanoma
Lead sponsor
Yana Najjar
Phase
Phase 1
Overall status
Active, not recruiting
Start date
November 29, 2021
Completion date
August 5, 2027
Enrollment
50 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

antineoplastic agents, antineoplastic agents, immunological, immune checkpoint inhibitors, melanoma, molecular mechanisms of pharmacological action, neoplasms, neoplasms by histologic type, neoplasms by site, nivolumab, unresectable solid tumors